Advertising

ISHARES DOW JONES US MEDICAL DEV.(ETF)

IHI-N

NYSEARCA:IHI

65.02
1.10 (1.66%)
Sustainability Characteristics can help investors integrate non-financial, sustainability considerations into their investment process. These metrics enable investors to evaluate funds based on their environmental, social, and governance (ESG) risks and opportunities. This analysis can provide insight into the effective management and long-term financial prospects of a fund. Learn more. The metrics below have been provided for transparency and informational purposes only. The existence of an ESG rating is not indicative of how or whether ESG factors will be integrated into a fund. The metrics are based on MSCI ESG Fund Ratings and, unless otherwise stated in fund documentation and included within a fund’s investment objective, do not change a fund’s investment objective or constrain the fund’s investable universe, and there is no indication that an ESG or Impact focused investment strategy or exclusionary screens will be adopted by a fund. For more information regarding a fund's investment strategy, please see the fund's prospectus.
More at Wikipedia

Analysis and Opinions about IHI-N

Signal
Opinion
Expert
Chart
BUY
BUY
August 3, 2021

Happy to own this, outperforming XLV, for instance. It's diversified. ZUH is another option, because it covers pharmas, hospital management and other areas. IHI, as a hospital provider, is pretty good.

Show full opinionHide full opinion

Happy to own this, outperforming XLV, for instance. It's diversified. ZUH is another option, because it covers pharmas, hospital management and other areas. IHI, as a hospital provider, is pretty good.

John Hood
Price
$63.490
Owned
Yes
BUY
BUY
April 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Show full opinionHide full opinion

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

David Burrows
Price
$360.725
Owned
Unknown
PARTIAL SELL
PARTIAL SELL
November 3, 2020
This ETF has smashed it over the past 5 years. Medical devices are a hybrid of tech and healthcare, which he really likes. Problem is that market enthusiasm and growth are priced in here already (like the FAANGs). Take profits.
Show full opinionHide full opinion
This ETF has smashed it over the past 5 years. Medical devices are a hybrid of tech and healthcare, which he really likes. Problem is that market enthusiasm and growth are priced in here already (like the FAANGs). Take profits.
Tyler Mordy
Price
$307.020
Owned
Unknown
BUY
BUY
April 8, 2020
It specializes in medical devices and equipment. He has held this over a year and a half. He likes the diversification it offers. He is not sure which of the holdings are involved in manufacturing defibrillators.
Show full opinionHide full opinion
It specializes in medical devices and equipment. He has held this over a year and a half. He likes the diversification it offers. He is not sure which of the holdings are involved in manufacturing defibrillators.
John Hood
Price
$239.735
Owned
Yes
DON'T BUY
DON'T BUY
February 25, 2020
It's very nichy, though it offers good exposure to healthcare. It's a high-beta play on healthcare, biotech and medical devices. His main worry is uncertainty around the US election, namely Bernie Sanders. If he nationalizes medical care, then this ETF will suffer.
Show full opinionHide full opinion
It's very nichy, though it offers good exposure to healthcare. It's a high-beta play on healthcare, biotech and medical devices. His main worry is uncertainty around the US election, namely Bernie Sanders. If he nationalizes medical care, then this ETF will suffer.
Tyler Mordy
Price
$256.900
Owned
Unknown
BUY
BUY
December 27, 2019
He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.
Show full opinionHide full opinion
He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.
Richard Croft
Price
$264.960
Owned
No
PAST TOP PICK
PAST TOP PICK
October 3, 2019
(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.
Show full opinionHide full opinion
(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.
Cameron Hurst
Price
$241.940
Owned
No
TOP PICK
TOP PICK
October 3, 2019
He loves it. It was flat over the last quarter. He is sticking with it.
Show full opinionHide full opinion
He loves it. It was flat over the last quarter. He is sticking with it.
Cameron Hurst
Price
$241.940
Owned
Yes
PAST TOP PICK
PAST TOP PICK
September 13, 2019

(A Top Pick Aug 15/18, Up 20%) A good way to play pharma without the litigation problems. For a Canadian one, it would be ZUH. Medical devices have done very well, and wish he had more.

Show full opinionHide full opinion

(A Top Pick Aug 15/18, Up 20%) A good way to play pharma without the litigation problems. For a Canadian one, it would be ZUH. Medical devices have done very well, and wish he had more.

John Hood
Price
$248.790
Owned
Yes
TOP PICK
TOP PICK
September 11, 2019
A perennial favorite for him. Worldwide hospital spending, global spending and Type II diabetes on the rise all make this a good holding. It is fairly high beta, so if the market falls this will fall too. Yield 0.31%
Show full opinionHide full opinion
A perennial favorite for him. Worldwide hospital spending, global spending and Type II diabetes on the rise all make this a good holding. It is fairly high beta, so if the market falls this will fall too. Yield 0.31%
Cameron Hurst
Price
$248.420
Owned
Yes
TOP PICK
TOP PICK
August 7, 2019
The only area of healthcare he remains invested in. The demographics are creating tailwinds. An aging population and growing obesity is good for this. Good cash flow holdings and good diversification. Yield 0.32%
Show full opinionHide full opinion
The only area of healthcare he remains invested in. The demographics are creating tailwinds. An aging population and growing obesity is good for this. Good cash flow holdings and good diversification. Yield 0.32%
Cameron Hurst
Price
$241.305
Owned
Yes
PAST TOP PICK
PAST TOP PICK
July 10, 2019
(A Top Pick Jul 11/18, Up 19%) A great example of demographic and diabetes trends that has created huge growth in demand. A sad, but profitable story. Not a defensive stock and has beta with the market.
Show full opinionHide full opinion
(A Top Pick Jul 11/18, Up 19%) A great example of demographic and diabetes trends that has created huge growth in demand. A sad, but profitable story. Not a defensive stock and has beta with the market.
Cameron Hurst
Price
$243.330
Owned
Yes
PAST TOP PICK
PAST TOP PICK
June 5, 2019
(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.
Show full opinionHide full opinion
(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.
Cameron Hurst
Price
$228.090
Owned
Yes
BUY
BUY
May 9, 2019
He likes this. Medical devices play to an aging demographic. The risk is political intereference with governments issuing new laws that interfere with this sector.
Show full opinionHide full opinion
He likes this. Medical devices play to an aging demographic. The risk is political intereference with governments issuing new laws that interfere with this sector.
Richard Croft
Price
$223.050
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
May 8, 2019
(A Top Pick May 09/18, Up 16%) He sees this continuing to be a good performer. It will follow the market up and down, but will do a little better in the long run. The ETF helps reduce the risk of picking a single company. He has backed away from healthcare, but still still holds this.
Show full opinionHide full opinion
(A Top Pick May 09/18, Up 16%) He sees this continuing to be a good performer. It will follow the market up and down, but will do a little better in the long run. The ETF helps reduce the risk of picking a single company. He has backed away from healthcare, but still still holds this.
Cameron Hurst
Price
$223.080
Owned
Yes
Showing 1 to 15 of 42 entries

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for ISHARES DOW JONES US MEDICAL DEV.(ETF) is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI-N) Frequently Asked Questions

What is ISHARES DOW JONES US MEDICAL DEV.(ETF) stock symbol?

ISHARES DOW JONES US MEDICAL DEV.(ETF) is a American stock, trading under the symbol IHI-N on the NYSE Arca (IHI). It is usually referred to as AMEX:IHI or IHI-N

Is ISHARES DOW JONES US MEDICAL DEV.(ETF) a buy or a sell?

In the last year, 3 stock analysts published opinions about IHI-N. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for ISHARES DOW JONES US MEDICAL DEV.(ETF).

Is ISHARES DOW JONES US MEDICAL DEV.(ETF) a good investment or a top pick?

ISHARES DOW JONES US MEDICAL DEV.(ETF) was recommended as a Top Pick by John Hood on 2021-08-03. Read the latest stock experts ratings for ISHARES DOW JONES US MEDICAL DEV.(ETF).

Why is ISHARES DOW JONES US MEDICAL DEV.(ETF) stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is ISHARES DOW JONES US MEDICAL DEV.(ETF) worth watching?

3 stock analysts on Stockchase covered ISHARES DOW JONES US MEDICAL DEV.(ETF) In the last year. It is a trending stock that is worth watching.

What is ISHARES DOW JONES US MEDICAL DEV.(ETF) stock price?

On 2021-09-20, ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI-N) stock closed at a price of $65.022.